ro 31-8220 has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies
Ro 31-8220: a protein kinase C inhibitor
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiota, M | 1 |
| Yokomizo, A | 1 |
| Takeuchi, A | 1 |
| Imada, K | 1 |
| Kashiwagi, E | 1 |
| Song, Y | 1 |
| Inokuchi, J | 1 |
| Tatsugami, K | 1 |
| Uchiumi, T | 1 |
| Naito, S | 1 |
1 other study available for ro 31-8220 and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Huma | 2014 |